Karı̈n Gogat

1.2k total citations · 1 hit paper
16 papers, 906 citations indexed

About

Karı̈n Gogat is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Karı̈n Gogat has authored 16 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 6 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Karı̈n Gogat's work include Chronic Myeloid Leukemia Treatments (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (4 papers). Karı̈n Gogat is often cited by papers focused on Chronic Myeloid Leukemia Treatments (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (4 papers). Karı̈n Gogat collaborates with scholars based in France, United States and Germany. Karı̈n Gogat's co-authors include Jörge E. Cortes, Tim H. Brümmendorf, Carlo Gambacorti‐Passerini, Athena Countouriotis, Hagop M. Kantarjian, Iryna Dyagil, Hemant Malhotra, Laimonas Griškevičius, Dong‐Wook Kim and Christine Powell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Molecular and Cellular Biology.

In The Last Decade

Karı̈n Gogat

16 papers receiving 894 citations

Hit Papers

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phas... 2012 2026 2016 2021 2012 100 200 300

Peers

Karı̈n Gogat
Dan Rohle United States
Marianne E. Greene United States
Cezary Swider United States
Maryellen C. Sparkes United States
Baohua Sun United States
Dan Rohle United States
Karı̈n Gogat
Citations per year, relative to Karı̈n Gogat Karı̈n Gogat (= 1×) peers Dan Rohle

Countries citing papers authored by Karı̈n Gogat

Since Specialization
Citations

This map shows the geographic impact of Karı̈n Gogat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karı̈n Gogat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karı̈n Gogat more than expected).

Fields of papers citing papers by Karı̈n Gogat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karı̈n Gogat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karı̈n Gogat. The network helps show where Karı̈n Gogat may publish in the future.

Co-authorship network of co-authors of Karı̈n Gogat

This figure shows the co-authorship network connecting the top 25 collaborators of Karı̈n Gogat. A scholar is included among the top collaborators of Karı̈n Gogat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karı̈n Gogat. Karı̈n Gogat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Pautas, Cécile, Emmanuel Raffoux, Juliette Lambert, et al.. (2021). Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia. Bone Marrow Transplantation. 56(6). 1474–1477. 13 indexed citations
2.
Pautas, Cécile, Emmanuel Raffoux, Juliette Lambert, et al.. (2018). Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia. Blood. 132(Supplement 1). 28–28. 5 indexed citations
3.
Brümmendorf, Tim H., Jörge E. Cortes, Cármino Antônio De Souza, et al.. (2014). Bosutinib versus imatinib in newly diagnosed chronic‐phase chronic myeloid leukaemia: results from the 24‐month follow‐up of the BELA trial. British Journal of Haematology. 168(1). 69–81. 148 indexed citations
4.
Hsyu, Poe‐Hirr, Karı̈n Gogat, Ladan Duvillié, Virginia Kelly, & Nadine Besson. (2012). Pharmacokinetics and Tolerability of Bosutinib in Asian Versus Non-Asian Patients with Philadelphia Chromosome–Positive Leukemia. Blood. 120(21). 4440–4440. 1 indexed citations
5.
Brümmendorf, Tim H., Hagop M. Kantarjian, Carlo Gambacorti‐Passerini, et al.. (2012). Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study. Blood. 120(21). 69–69. 20 indexed citations
6.
Gambacorti‐Passerini, Carlo, Tim H. Brümmendorf, Dong-Wook Kim, et al.. (2012). Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial. Blood. 120(21). 4442–4442. 2 indexed citations
7.
Cortes, Jörge E., Dong‐Wook Kim, Hagop M. Kantarjian, et al.. (2012). Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. Journal of Clinical Oncology. 30(28). 3486–3492. 344 indexed citations breakdown →
8.
Gambacorti‐Passerini, Carlo, Dong‐Wook Kim, Hagop M. Kantarjian, et al.. (2010). An Ongoing Phase 3 Study of Bosutinib (SKI-606) Versus Imatinib In Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Blood. 116(21). 208–208. 31 indexed citations
9.
Gogat, Karı̈n, Céline Bouquet, Magali Saint‐Geniez, et al.. (2003). In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Therapy. 10(25). 2098–2103. 34 indexed citations
10.
Gogat, Karı̈n, Loïc Van Den Berghe, Alexandra Kobetz, et al.. (2003). The β3 Integrin Gene is Expressed at High Levels in the Major Haematopoietic and Lymphoid Organs, Vascular System, and Skeleton During Mouse Embryo Development. Cell Communication & Adhesion. 10(3). 129–140. 8 indexed citations
11.
Gogat, Karı̈n, Loïc Van Den Berghe, Alexandra Kobetz, et al.. (2003). The β3 Integrin Gene is Expressed at High Levels in the Major Haematopoietic and Lymphoid Organs, Vascular System, and Skeleton During Mouse Embryo Development. Cell Communication & Adhesion. 10(3). 129–140. 1 indexed citations
12.
Marchant, Dominique, Karı̈n Gogat, P. Dureau, et al.. (2002). Use of denaturing HPLC and automated sequencing to screen the VMD2 gene for mutations associated with Best's vitelliform macular dystrophy. Ophthalmic Genetics. 23(3). 167–174. 7 indexed citations
13.
Cherqui, Stéphanie, Caroline Sevin, Ghislaine Hamard, et al.. (2002). Intralysosomal Cystine Accumulation in Mice Lacking Cystinosin, the Protein Defective in Cystinosis. Molecular and Cellular Biology. 22(21). 7622–7632. 130 indexed citations
14.
Marchant, Dominique, Karı̈n Gogat, Sandrine Boutboul, et al.. (2001). Identification of novel VMD2 gene mutations in patients with best vitelliform macular dystrophy. Human Mutation. 17(3). 235–235. 37 indexed citations
15.
Bonnel, Sébastien, Karı̈n Gogat, Loïc Van Den Berghe, et al.. (2001). Prominent Beta-5 Gene Expression in the Cardiovascular System and in the Cartilaginous Primordiae of the Skeleton During Mouse Development. Cell Communication & Adhesion. 8(3). 99–112. 9 indexed citations
16.
Nandrot, Emeline F., Éric Dufour, Alexandra Provost, et al.. (2000). Homozygous Deletion in the Coding Sequence of the c-mer Gene in RCS Rats Unravels General Mechanisms of Physiological Cell Adhesion and Apoptosis. Neurobiology of Disease. 7(6). 586–599. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026